Literature DB >> 2982736

Resistance to adenovirus infection after administration of Bordetella pertussis vaccine in mice.

A L Winters, D W Baggett, W R Benjamin, H K Brown, T W Klein.   

Abstract

Treatment of mice with Bordetella pertussis vaccine rendered mice resistant to mouse adenovirus infection. The resistant state took at least 5 days to develop, and susceptibility returned to a portion of the test population 35 days after treatment. Transient resistance developed in congenitally athymic mice also. Treatment with a dose of 25 micrograms (dry weight) of B. pertussis vaccine protected approximately 50% of the test population. Vaccines prepared from several different strains of B. pertussis were capable of inducing resistance, and the induction of resistance was not dependent on the mouse strain used for testing. Cross-reacting antibodies capable of neutralizing the virus or protecting against a challenging infection were not induced by treatment with B. pertussis vaccine.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2982736      PMCID: PMC261326          DOI: 10.1128/iai.47.3.587-591.1985

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  19 in total

1.  Circulating and tissue hematocrits of normal unanesthetized mice.

Authors:  J J FRIEDMAN
Journal:  Am J Physiol       Date:  1959-02

2.  Bacterial allergy increases susceptibility to influenza virus in mice.

Authors:  I A PARFENTJEV
Journal:  Proc Soc Exp Biol Med       Date:  1955-11

3.  Protection of mice against viral infection by Corynebacterium parvum and Bordetella pertussis.

Authors:  H Kirchner; M T Scott; H M Hirt; K Munk
Journal:  J Gen Virol       Date:  1978-10       Impact factor: 3.891

4.  Duodenal lesions associated with adenovirus infection in athymic "nude" mice.

Authors:  A L Winters; H K Brown
Journal:  Proc Soc Exp Biol Med       Date:  1980-07

5.  Biphasic effect of pertussis vaccine on serum insulin in mice.

Authors:  E L Hewlett; C O Roberts; J Wolff; C R Manclark
Journal:  Infect Immun       Date:  1983-07       Impact factor: 3.441

6.  Separation and purification of the hemagglutinins from Bordetella pertussis.

Authors:  Y Sato; J L Cowell; H Sato; D G Burstyn; C R Manclark
Journal:  Infect Immun       Date:  1983-07       Impact factor: 3.441

7.  Characteristics of cells present in peritoneal fluids of mice injected intraperitoneally with Bordetella pertussis.

Authors:  C W Fishel; D G Halkias; T W Klein; A Szentivanyi
Journal:  Infect Immun       Date:  1976-01       Impact factor: 3.441

8.  Biological activities of fragments derived from Bordetella pertussis endotoxin: isolation of a nontoxic, Shwartzman-negative lipid A possessing high adjuvant properties.

Authors:  G Ayme; M Caroff; R Chaby; N Haeffner-Cavaillon; A Le Dur; M Moreau; M Muset; M C Mynard; M Roumiantzeff; D Schulz; L Szabó
Journal:  Infect Immun       Date:  1980-03       Impact factor: 3.441

9.  Protection against lethal viral infection by neutralizing and nonneutralizing monoclonal antibodies: distinct mechanisms of action in vivo.

Authors:  L Lefrancois
Journal:  J Virol       Date:  1984-07       Impact factor: 5.103

10.  A single genetic element in H-2K affects mouse T-cell antiviral function in poxvirus infection.

Authors:  U Kees; R V Blanden
Journal:  J Exp Med       Date:  1976-02-01       Impact factor: 14.307

View more
  2 in total

Review 1.  Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies.

Authors:  Seema Mattoo; James D Cherry
Journal:  Clin Microbiol Rev       Date:  2005-04       Impact factor: 26.132

2.  Bordetella pertussis infection exacerbates influenza virus infection through pertussis toxin-mediated suppression of innate immunity.

Authors:  Victor I Ayala; John R Teijaro; Donna L Farber; Susan G Dorsey; Nicholas H Carbonetti
Journal:  PLoS One       Date:  2011-04-20       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.